Name | Type | Posted | Actions |
|---|---|---|---|
Salient Characteristics Qiagen LIAISON QuantiFERON TB Gold Plus and Control.pdf | Sep 16, 2025 |
Reagents for detection of Mycobacterium Tuberculosis: Liaison QuantiFERON TB Gold Plus and LIAISON Control QuantiFERON TB Gold Plus
Contact and place of performance
Brittany Chartier
Tacoma, WA
USA
THIS NOTICE OF INTENT IS NOT A REQUEST FOR QUOTES. A DETERMINATION NOT TO COMPETE THE PROPOSED PROCUREMENT BASED UPON RESPONSES TOTHIS NOTICE IS SOLELY WITHIN THE DISCRETION OF THE GOVERNMENT. Medical Readiness Contracting Office - Pacific hereby provides notice of its intent to award a sole-source, firm fixed price contract under the authority of FAR 13.106-1(b)(1). As a result, the Government intends to award direc...
View moreThe attached salient characteristics detail the requirements of this anticipated contract action. Market Research has demonstrated that the intended awardee is the only business that is able to meet the requirements.
THIS NOTICE OF INTENT IS NOT A REQUEST FOR QUOTES; no solicitation or RFQ will be forthcoming.
Any firm that believes it can provide the stated supplies can provide supporting documents demonstrating their capabilities and certifications. Interested parties may identify their interest and capability to respond to this requirement no later than Wednesday, 17 September 2025 at 11:00 AM Pacific Time.
All documents submitted will not be returned. Responses received may be used for future acquisitions. All interested parties shall submit clear and convincing documentation demonstrating their capabilities to satisfy the requirements contained within the attached Statement of Work. The capability documentation should include general information and technical background describing in detail the prospective contractor's capabilities and experience that will demonstrate the ability to support these requirements.
Interested parties are encouraged to furnish information by email only with subject line stating - RESPONSE TO INTENT TO SOLE SOURCE FOR W81K0225QA107. Information can be sent to Brittany Chartier at [email protected]. No telephone or facsimile requests will be accepted. This procurement will be prepared in accordance with FAR Part 13, Simplified Acquisition Procedures.
Medical Readiness Contracting Office - Pacific will NOT be responsible for any costs incurred by interested parties in responding to this notice of intent. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
The Department of the Army, through the Medical Readiness Contracting Office - Pacific, has issued a notice of intent to award a sole-source, firm-fixed-price indefinite delivery indefinite quantity (IDIQ) contract to Qiagen, LLC. This requirement covers the procurement of QuantiFERON TB Gold-Plus assay reagents for the detection of Mycobacterium tuberculosis immune responses via enzyme immunoassay at Madigan Army Medical Center in Tacoma, WA. The anticipated contract features a five-year ordering period to ensure continuity of operations and maintain testing capacity for the facility’s Defense Health Agency reference laboratory obligations.
The procurement is classified under NAICS 325413 for In-Vitro Diagnostic Substance Manufacturing and PSC 6550 for In Vitro Diagnostic Substances, Reagents, Test Kits and Sets. There is no set-aside assigned to this action. The government intends to award this contract to Qiagen, LLC because their QuantiFERON TB Gold-Plus assays are the only FDA-cleared interferon-gamma release assays compatible with the center’s existing DiaSorin LIAISON XL analyzer. Utilizing alternative products would require the purchase of additional instrumentation and physical workspace that the facility cannot accommodate.
This notice, identified by solicitation number W81K0225QA107, is not a request for quotes. However, the agency will consider capability statements and technical documentation from firms that believe they can satisfy the requirements. Responses must be submitted via email to Brittany Chartier by the deadline of September 17, 2025, at 11:00 AM Pacific Time. Supporting documentation for the requirement is included in a single attachment detailing the salient characteristics of the reagents and controls.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.